Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing results

How to ensure accurate NeuroQuant® processing results

In this post, I review additional causes affecting goodness of fit which can result in NeuroQuant being unable to segment specific brain structures and issuing a processing error message. Previous posts discussed why contrast agents are not used to achieve quality segmentation with NeuroQuant, and examined why good alignment to atlas is necessary for accurate NeuroQuant output.

Ensuring proper processing is an important factor in NeuroQuant’s analysis process. To achieve its high quality segmentation results, NeuroQuant verifies each patient’s brain image can be processed correctly. This safeguards the accuracy of the segmentation results and therefore, the accuracy of the calculated volumes.

Patients who have shunts, implants or other artifacts or inherent abnormalities, can potentially generate segmentation misregistration. To prevent such errors and protect the accuracy of the results, NeuroQuant prevents analysis when such artifacts or anatomical anomalies are present.

In some cases, such as the first example below, a shunt in the patient’s brain made good alignment to atlas impossible, resulting in a processing failure.

Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing resultsIn the second example, a patient’s excess cranial tissue prevented proper processing and resulted in an error message.

Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing resultsMore information about using and processing NeuroQuant can be found here.

More Resources

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”

07/16/2025

Advancing Prostate MRI with Restriction Spectrum Imaging

Why is OnQ Prostate unique, and what makes it a game-changer for clinicians?
Scroll to Top